Why the study?
Evidence to support intraoperative lidocaine dosing regimens in obesity is lacking, risking underdosing or toxicity.
What are the pharmacokinetic parameters of a fixed lean body weight-based intravenous lidocaine dosing regimen in obese patients undergoing elective laparoscopic abdominal surgery?
What are the pharmacokinetic parameters of a fixed lean body weight-based intravenous lidocaine dosing regimen in obese patients undergoing elective laparoscopic abdominal surgery?
A lean body weight-based dosing regimen for intraoperative intravenous lidocaine yields consistent pharmacokinetic parameters across different classes of obesity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: